COMPOSITE PHYSIOLOGIC INDEX IN IDIOPATHIC PULMONARY FIBROSIS: EFFECTS OF NINTEDANIB

被引：0
|
作者：
Glaspole, I [1 ,2 ]
Wells, A. [3 ,4 ]
Behr, J. [5 ,6 ]
Stansen, W. [7 ]
Stowasser, S. [7 ]
Maher, T. [3 ,4 ]
机构：
[1] Alfred Hosp, Melbourne, Vic, Australia
[2] Monash Univ, Melbourne, Vic, Australia
[3] Royal Brompton & Harefield NHS Fdn Trust, Natl Inst Hlth Res Resp Biomed Res Unit, London, England
[4] Imperial Coll, Natl Heart & Lung Inst, London, England
[5] Univ Munich, Med Klin & Poliklin 5, Munich, Germany
[6] German Ctr Lung Res, Asklepios Klin Munchen Gauting, Munich, Germany
[7] Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim, Germany
来源：
RESPIROLOGY | 2018年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
TP 037
引用
收藏
页码：125 / 125
页数：1
相关论文
共 50 条
  • [1] Nintedanib Reduces Disease Progression in Patients With Idiopathic Pulmonary Fibrosis Irrespective of Composite Physiologic Index at Baseline in the INPULSIS Trials
    Wells, Athol
    Behr, Juergen
    Stansen, Wibke
    Stowasser, Susanne
    Maher, Toby
    [J]. CHEST, 2016, 150 (04) : 539A - 539A
  • [2] Nintedanib for Idiopathic Pulmonary Fibrosis
    Tepede, Abisola
    Yogaratnam, Dinesh
    [J]. JOURNAL OF PHARMACY PRACTICE, 2019, 32 (02) : 199 - 206
  • [3] NINTEDANIB IN IDIOPATHIC PULMONARY FIBROSIS
    Woodcock, H. V.
    Maher, T. M.
    [J]. DRUGS OF TODAY, 2015, 51 (06) : 345 - 356
  • [4] Nintedanib in idiopathic pulmonary fibrosis
    Venkatesan, Priya
    [J]. LANCET RESPIRATORY MEDICINE, 2021, 9 (11): : E108 - E108
  • [5] Longitudinal Changes In The Composite Physiologic Index And Pulmonary Function In Patients With Idiopathic Pulmonary Fibrosis And Emphysema
    Schmidt, S. L.
    Sundaram, B.
    Tayob, N.
    Han, M. K.
    Nambiar, A.
    Kazerooni, E. A.
    Gross, B. H.
    Chughtai, A.
    Myers, J. L.
    Flint, A.
    Murray, S.
    Toews, G. B.
    Martinez, F. J.
    Flaherty, K. R.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2010, 181
  • [6] Nintedanib for the Idiopathic Pulmonary Fibrosis with Emphysema
    Krome, Susanne
    [J]. PNEUMOLOGIE, 2019, 73 (03):
  • [7] Nintedanib for the treatment of idiopathic pulmonary fibrosis
    Varone, Francesco
    Sgalla, Giacomo
    Iovene, Bruno
    Bruni, Teresa
    Richeldi, Luca
    [J]. EXPERT OPINION ON PHARMACOTHERAPY, 2018, 19 (02) : 167 - 175
  • [8] Nintedanib in the treatment of idiopathic pulmonary fibrosis
    Mazzei, Mariano E.
    Richeldi, Luca
    Collard, Harold R.
    [J]. THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE, 2015, 9 (03) : 121 - 129
  • [9] Effects of nintedanib in patients with idiopathic pulmonary fibrosis by GAP stage
    Ryerson, Christopher J.
    Kolb, Martin
    Richeldi, Luca
    Lee, Joyce
    Wachtlin, Daniel
    Stowasser, Susanne
    Poletti, Venerino
    [J]. ERJ OPEN RESEARCH, 2019, 5 (02)
  • [10] Comparison of Composite Physiologic Index and GAP Models in Patients with Idiopathic Pulmonary Fibrosis: A Nationwide Cohort Study
    Sung, M.
    Hoon, L. Sang
    Kang, Y.
    Ahn, C.
    Park, M.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2018, 197
12345